Head-to-head · free

Stevanato Group S.p.A. vs TransMedics Group, Inc.

STVN vs TMDX — return on capital, cash generation, margins and balance sheet side by side.

STVN

0 / 4

measures where STVN leads

TMDX

4 / 4

measures where TMDX leads

A simple count of which company scores better on each measure — not a recommendation to buy or sell.

MeasureSTVNTMDX · FY2025
Revenue—$605.5M
Net income—$190.3M
Revenue growth (yearly, multi-year)—111.5%
Free cash flow—$133.6M
Free cash flow margin—22.1%
Net cash / (debt)——
ROIC7.7%—
Return on equity9.7%54.2%
Gross margin29.0%59.9%
Operating margin16.8%17.9%
Net debt / EBITDA1.13x0.18x

Figures are as reported by each company; latest fiscal year shown.

Where Stevanato Group S.p.A.'s cash went

Not reported yet.

Full STVN profile →

Where TransMedics Group, Inc.'s cash went (FY2025)

Capital spending
$59.3M
Buybacks
—
Dividends
—
Acquisitions
—
Net debt issued / (repaid)
—
Full TMDX profile →

Ask which business is stronger

"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.

Compare them free

More comparisons